Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (95 total)
-
Creator: FDA
Subject: Treatment & Care
Item Type: Guide
Date Last Updated: 2022-04
Description: JYNNEOS is a vaccine indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.Includes: indications and usage, dosage and administration, dosage… -
Creator: CDC
Subject: Treatment & Care
Item Type: Guide
Date Last Updated: 2022-08-23
Description: VACCINE INFORMATION STATEMENT -
Creator: NETEC
Subject: Treatment & Care
Item Type: Video
Date Last Updated: 2022-09-09
Description: In this video, we demonstrate the technique of intradermal medication administration. In the 2022 monkeypox outbreak, this technique is being used to administer the Jynneos smallpox and monkeypox vaccine in order to increase the number of available… -
Creator: Li, L., L. B. Robinson, R. Patel, A. B. Landman, X. Fu, E. S. Shenoy, D. M. Hashimoto, A. Banerji, P. G. Wickner, U. Samarakoon, C. M. Mancini, Y. Zhang, and K. G. Blumenthal.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-10-01
Description: Allergic history in individuals with confirmed anaphylaxis to a messenger RNA (mRNA) COVID-19 vaccine is common. However, the risk factors for allergy symptoms after receiving the vaccine are unknown. -
Creator: Bar-On, Yinon M., Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, and Amit Huppert.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-10-07
Description: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5… -
Creator: Xia, ShengLi, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-09-15
Description: Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control.… -
Creator: Barda, Noam, Noa Dagan, Yatir Ben-Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A. Hernán, Marc Lipsitch, Isaac Kohane, Doron Netzer, Ben Y. Reis, and Ran D. Balicer.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-08-25
Description: Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the… -
Creator: The Medical Letter on Drugs and Therapeutics
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-07-15
Description: COVID-19 Vaccine Comparison Chart (online only) effectiveness by vaccine and by variant. -
Creator: Kamar, Nassim, Florence Abravanel, Olivier Marion, Chloé Couat, Jacques Izopet, and Arnaud Del Bello.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-23
Description: A weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in recipients of solid-organ transplants. -
Creator: the ENSEMBLE Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-10
Description: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.